Clinical Trial Update: Metronomic Chemotherapy of Capecitabine After Standard Adjuvant Chemotherapy in Operable Triple Negative Breast Cancer

View source ↗

Summary

This document reports on a clinical trial evaluating metronomic capecitabine after standard adjuvant chemotherapy in operable triple-negative breast cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• Xeloda (capecitabine)

Snippet

Sponsor: Xijing Hospital | Conditions: Breast Cancer, Capecitabine | Status: UNKNOWN